Skip to main content

Latest news


Catch up with the latest research news, approvals, and guideline updates in oncology.


More breast cancer news

05-06-2023 | Breast cancer | Conference coverage | News

Adjuvant ribociclib reduces recurrence risk in early breast cancer

Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

Young girl having ECG

31-05-2023 | Cardiotoxicity | News

Anthracyclines may increase heart failure risk among YA cancer survivors

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

05-05-2023 | Breast cancer | News

DESTINY-Breast02 supports T-DXd as ‘preferred’ regimen after progression on T-DM1

Patients with HER2-positive metastatic breast cancer that is refractory or resistant to trastuzumab emtansine have significantly better outcomes with trastuzumab deruxtecan than a physician’s choice treatment, shows the phase 3 DESTINY-Breast02 trial.

Pregnant woman on drip

24-04-2023 | Pregnancy | News

Increased 5-year mortality risk for cancers diagnosed during pregnancy, postpartum

Pregnancy-associated cancers may be linked to an elevated 5-year mortality risk, but the risk varies by tumor site and time of diagnosis, suggests a population-based cohort study.

Genitourinary cancers news

20-10-2023 | Prostate cancer | News

Enzalutamide use supported for biochemically recurrent prostate cancer

Men with localized prostate cancer and high-risk biochemical recurrence benefit from treatment with enzalutamide, either alongside leuprolide or alone.

Man receiving radiotherapy

06-10-2023 | Prostate cancer | News

Add-on SBRT improves outcomes of men with oligometastatic CRPC

Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.

More genitourinary cancers news

08-08-2023 | Renal cell carcinoma | News

Potential of pembrolizumab plus lenvatinib for non-clear-cell RCC shown

The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

Patient taking tablets

30-06-2023 | Prostate cancer | News

First-line talazoparib plus enzalutamide supported for mCRPC

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

Young girl having ECG

31-05-2023 | Cardiotoxicity | News

Anthracyclines may increase heart failure risk among YA cancer survivors

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

Transgender symbol

09-05-2023 | Prostate cancer | News

Prostate cancer in transgender women ‘not so rare’

A chart review of the Veterans Affairs health system indicates that there are around 14 cases of prostate cancer per year among transgender women.

Lung & thoracic cancers news

29-09-2023 | Adverse events | News

Trial adds to evidence for risk-based thromboprophylaxis in people with cancer

Findings from the TARGET-TP trial support a risk-directed approach to thromboprophylaxis in ambulatory patients with gastrointestinal or lung cancer receiving systemic anticancer treatment.

22-09-2023 | KRAS inhibitors | News

Novel KRAS inhibitor elicits ‘durable responses’ in KRAS G12C mutation-positive tumors

The novel KRAS inhibitor divarasib has shown promise in previously treated patients with advanced solid tumors harboring a KRAS G12C mutation.

More lung & thoracic cancers news

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox


The Medicine Matters news service is brought to you in partnership with medwireNews